Differential action of hepatic sympathetic neuropeptides: metabolic action of galanin, vascular action of NPY
- 1 March 2000
- journal article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 278 (3) , E390-E397
Abstract
Activation of hepatic nerves increases both hepatic glucose production (HGP) and hepatic arterial vasoconstriction, the latter best described by a decrease of hepatic arterial conductance (HAC). Because activation of canine hepatic nerves releases the neuropeptides galanin and neuropeptide Y (NPY) as well as the classical neurotransmitter norepinephrine (NE), we sought to determine the relative role of these neuropeptides vs. norepinephrine in mediating metabolic and vascular responses of the liver. We studied the effects of local exogenous infusions of galanin and NPY on HGP and HAC to predict the metabolic and vascular function of endogenously released neuropeptide. Galanin (n = 8) or NPY (n = 4) was infused with and without NE directly into the common hepatic artery of halothane-anesthetized dogs, and we measured changes in HGP and HAC. A low dose of exogenous galanin infused directly into the hepatic artery potentiated the HGP response to NE yet had little effect on HGP when infused alone. The same dose of galanin infused into a peripheral vein (n = 8) did not potentiate the HGP response to NE, suggesting that the locally infused galanin acted directly on the liver to modulate NE's metabolic action. In contrast, a large dose of exogenous NPY failed to influence HGP when infused either alone or in combination with NE. Finally, NPY, but not galanin, tended to decrease HAC when infused alone; neither neuropeptide potentiated the HAC response to NE. Therefore, both hepatic neuropeptides may contribute to the action of sympathetic nerves on liver metabolism and blood flow. It is likely that endogenous hepatic galanin acts directly on the liver to selectively modulate norepinephrine's metabolic action, whereas endogenous hepatic NPY acts independently of NE to cause vasoconstriction.Keywords
This publication has 39 references indexed in Scilit:
- Pharmacological Characteristics of the Canine Cerebrovascular Constriction Produced by Neuropeptide Y.Biological and Pharmaceutical Bulletin, 1995
- Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration.Journal of Clinical Investigation, 1991
- Localization of adrenergic and neuropeptide tyrosine-containing nerves in the mammalian liverHepatology, 1989
- Hepatic adrenoceptors involved in the glycogenolytic respone to exogenous (-)-norepinephrine in the dog liver in vivoLife Sciences, 1985
- Immunohistochemical mapping of galanin-like neurons in the rat central nervous systemPeptides, 1985
- Correlation between endogenous noradrenaline and glucose released from the liver upon hepatic sympathetic nerve stimulation in anesthetized dogsCanadian Journal of Physiology and Pharmacology, 1984
- Neuropeptide Y (NPY) depresses the secretion of 3H‐noradrenaline and the contractile response evoked by field stimulation, in rat vas deferensActa Physiologica Scandinavica, 1984
- Afferent and efferent neural roles in liver functionProgress in Neurobiology, 1983
- Direct Control of Glycogen Metabolism in the Perfused Rat Liver by the Sympathetic InnervationEuropean Journal of Biochemistry, 1982
- Conductance or Resistance?Nature, 1968